期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

R-CHOP方案治疗68例弥漫大B细胞淋巴瘤不良反应的观察及护理 被引量：3

Observation and Nursing Care of Diffuse Large B-cell Lymphoma of Adverse Reaction in Treatment of 68 Cases of R-CHOP Scheme
下载PDF
导出
摘要 弥漫大B细胞淋巴瘤（diffuse large B-Cell lymphoma，DLBCL）是临床最常见的一种非霍奇金淋巴瘤，约占所有非霍奇金淋巴瘤（non-Hodgkin lymphoma，NHL）的30％～40％。多年来，CHOP曾一度被视为治疗弥漫大B细胞淋巴瘤的标准治疗方案，
作者 王丽萍 马莉
机构地区 郑州市第九人民医院
出处 《河南科技大学学报（医学版）》 2013年第3期226-227,共2页 Journal of Henan University of Science & Technology:Medical Science
关键词 R—CHOP 弥漫大B细胞淋巴瘤 护理
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献1

二级参考文献40

  • 1Arce-Salinas, C.A., Rodriguez-Garcia, F., Gomez-Vargas, J.I., 2012. Long-term efficacy of anti-CD20 antibodies in re- fractory lupus nephritis. Rheumatol. Int., 32(5): 1245-1249. [doi:10.1007/s00296-010-1755-0].
  • 2Bingham, C.O., Looney, R.J., Deodhar, A., Halsey, N., Greenwald, M., Codding, C., Trzaskoma, B., Martin, F., Agarwal, S., Kelman, A., 2010. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum., 62(1):64-74. [doi:lO.1002/art.25034].
  • 3Calabrese, L.H., Molloy, E.S., Huang, D., Ransohoff, R.M., 2007. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum., 56(7):2116-2128. [doi: 10.1002/art.22657].
  • 4Catapano, F., Chaudhry, A.N., Jones, R.B., Smith, K.G., Jayne D.W., 2010. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol. Dial. Transplant., 25(11):3586-3592. [doi:10. 1093/ndt/gfq256].
  • 5Emery, P., Deodhar, A., Rigby, W.F., Isaacs, J.D., Combe, B., Racewicz, A.J., Latinis, K., Abud-Mendoza, C., Szczepanski, L.J., Roschmann, R.A., et al., 2010. Effi- cacy and safety of different doses and retreatment of ri-tuximab: a randomised, placebo-controlled trial in pa- tients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iN- adequate rEsponders (SERENE)). Ann. Rheum. Dis., 69(9):1629-1635. [doi:10.1136/ard.2009.119933].
  • 6Furie, R., Looney, R.J., Rovin, B., Latinis Kevin, M., Appel, G., Sanchez-Guerrero, J., 2009. Efficacy and safety of rituximab in subjects with active proliferative lupus ne- phritis (LN): results from the randomized, double-blind phase III LUNAR study [abstract]. Arthritis Rheum, 60(s10):1149. [doi:10.10021art.262231.
  • 7Gunnarsson, I., Sundelin, B., Jonsdottir, T., Jacobson, S.H., Henriksson, E.W., van Vollenhoven, R.F., 2007. Histo- pathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum., 56(4):1263-1272. [doi:10.1002/art.22505].
  • 8Houssiau, F.A., Vasconcelos, C., D'Cruz, D., 2002. Immuno- suppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum., 46(8):2121-2131. [doi:10.1002/art.10461].
  • 9Lateef, A., Lahiri, M., Teng, G.G., Vasoo, S., 2010. Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Lupus, 19(6): 765-770. [doi:10.1177/0961203309358599].
  • 10Leandro, M.J., Edwards, J.C., Cambridge, G., Ehrenstein, M.R., Isenberg, D.A., 2002. An open study of B lym- phocyte depletion in systemic lupus erythematosus. Arthritis Rheum., 46(10):2673-2677. [doi:10.1002/art. 10541].

共引文献11

同被引文献17

引证文献3

二级引证文献5

河南科技大学学报（医学版）
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部